Barclays lowered the firm’s price target on Bristol-Myers to $65 from $66 and keeps an Equal Weight rating on the shares. The analyst says the company’s Q1 update reinforces rather than addresses key questions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on BMY: